CN Patent

CN108210454A — 一种帕布昔利布的口服乳剂及其制备方法

Assigned to Shenzhen Institute Of Nanjing University · Expires 2018-06-29 · 8y expired

What this patent protects

本发明属于制药领域，具体涉及一种帕布昔利布的口服乳剂及其制备方法。该口服乳剂包括质量比为0.1～1％的帕布昔利布游离碱或其可药用盐、0.1～5％的药用酸性辅料、0.1～5％的甜味剂、0.01～0.5％的抗氧化剂、0.1～10％的药用油和1～10％的药用乳化剂。与常规制剂相比，本发明具有更优秀的口服吸收性质，可用于降低帕布昔利布的口服吸收差异和提高生物利用度。

USPTO Abstract

本发明属于制药领域，具体涉及一种帕布昔利布的口服乳剂及其制备方法。该口服乳剂包括质量比为0.1～1％的帕布昔利布游离碱或其可药用盐、0.1～5％的药用酸性辅料、0.1～5％的甜味剂、0.01～0.5％的抗氧化剂、0.1～10％的药用油和1～10％的药用乳化剂。与常规制剂相比，本发明具有更优秀的口服吸收性质，可用于降低帕布昔利布的口服吸收差异和提高生物利用度。

Drugs covered by this patent

Patent Metadata

Patent number
CN108210454A
Jurisdiction
CN
Classification
—
Expires
2018-06-29
Drug substance claim
No
Drug product claim
No
Assignee
Shenzhen Institute Of Nanjing University
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.